dromlakhani Avoid specific tests for TSHD diagnosis
STEP 1 — Gather Information
Collect history of childhood cancer treatment focusing on hypothalamic–pituitary axis radiation ≥30 Gy, tumor/surgery in the HP region, or presence of other HP axis deficits; note current free T4 and TSH results if available; identify if the clinician is considering serum T3, TSH surge analysis, or TRH stimulation for TSHD evaluation.
STEP 2 — Rule In / Rule Out
Rule in if the patient is at risk for TSHD (HP axis radiation ≥30 Gy, HP tumor/surgery, or other HP deficits) and the clinician is contemplating use of serum T3, TSH surge analysis, or TRH stimulation to diagnose TSHD; otherwise rule out.
STEP 3 — Classify or Stratify
Classify the scenario as “prohibited tests considered” when both at-risk status and consideration of the specific tests are present.
STEP 4 — Decide
Do not order serum triiodothyronine, thyroid-stimulating hormone surge analysis, or TRH stimulation; instead assess TSHD using free T4 and TSH (low/low-normal free T4 with non‑elevated TSH) and, if confirmed, initiate levothyroxine after verifying adequate adrenal function.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on serum T3, TSH surge analysis, or TRH stimulation as they are not indicative or predictive of TSHD and may yield misleading results; avoid diagnosing TSHD based on a single TSH measurement; ensure free T4 is measured by a reliable method (e.g., equilibrium dialysis if antiepileptics are used); do not start levothyroxine without assessing adrenal axis function.
Concrete Clinical Example
A 14‑year‑old survivor of medulloblastoma who received 36 Gy craniospinal irradiation presents with mild fatigue and weight gain; free T4 is at the low‑normal limit and TSH is 2.1 mIU/L; the clinician considers ordering a TRH stimulation test. Per the guideline, the test is not recommended; the clinician repeats free T4 in 4–6 weeks, finds it decreased below normal, and initiates low‑dose levothyroxine after confirming normal adrenal function.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175